Open company research · LONN
Lonza Group
Contract biologics manufacturing and process transfer
Sources checked 2026-10-21 · Source review; evidence limits noted belowResearch question
Validated mammalian production slots, technology transfer and batch release
What limits delivery, and how quickly can qualified alternatives expand?
Reported evidence
Lonza describes Vacaville as a cGMP mammalian site with 12,000 L and 25,000 L reactors and 332,000 L of stated capacity.
- Lonza: Vacaville manufacturing site ↗Source: date not provided · Checked 2026-10-21
- Lonza: SIX listing LONN ↗Source: date not provided · Checked 2026-10-21
Our interpretation
Reactor liters are a facility-scale measure, not released drug output, utilization or available commercial slots.
Capacity and delivery boundaries
- Issuer-stated Vacaville reactor capacity is 332,000 L. Current utilization, released batches and uncommitted slots are not disclosed on this site page. Source ↗
What to monitor
- Customer technology transfers, validated batches and utilization
- Released product output, project timing and returns on invested capital
What would weaken the case?
- Drug-program failures leave contracted capacity underutilized
- Competing CDMO capacity expands faster than demand
Economic exposure
Revenue tied to this specific constraint, pricing power and current valuation have not been quantified in this profile. These need a separate financial review.
Continue in the Atlas →